← Back to Screener
BioRestorative Therapies, Inc. Common Stock (NV) (BRTX)
Price$0.41
Value ScoreF
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-70.38%
Price vs S&P 500 (4W)96.80%
VGM Score32.67
Market Capitalization$10.32M
All Metrics
Book Value / Share (Quarterly)$0.12
P/TBV (Annual)1.25x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)44.18%
Cash Flow / Share (Quarterly)$-0.47
Price vs S&P 500 (YTD)-73.69%
Gross Margin (TTM)92.08%
Net Profit Margin (TTM)-3089.55%
EPS (TTM)$-1.09
10-Day Avg Trading Volume58.85M
EPS Excl Extra (TTM)$-1.09
Revenue Growth (5Y)35.07%
EPS (Annual)$-1.58
ROI (Annual)-3992.26%
Gross Margin (Annual)93.37%
Net Profit Margin (5Y Avg)-23470.44%
Cash / Share (Quarterly)$0.14
Revenue Growth QoQ (YoY)-7.32%
ROA (Last FY)-349.10%
Revenue Growth TTM (YoY)-8.47%
EBITD / Share (TTM)$-1.24
ROE (5Y Avg)-904.71%
Operating Margin (TTM)-3975.00%
Cash Flow / Share (Annual)$-1.23
P/B Ratio3.41x
P/B Ratio (Quarterly)2.29x
Net Income / Employee (Annual)$-1,095,500
EV / Revenue (TTM)20.14x
Net Interest Coverage (TTM)-23.34x
ROA (TTM)-193.30%
EPS Incl Extra (Annual)$-1.58
Current Ratio (Annual)0.84x
Quick Ratio (Quarterly)2.23x
3-Month Avg Trading Volume13.57M
52-Week Price Return-77.25%
Revenue / Employee (TTM)$27,500
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)28.69x
Asset Turnover (Annual)0.09x
52-Week High$2.04
Operating Margin (5Y Avg)-23650.23%
EPS Excl Extra (Annual)$-1.58
CapEx CAGR (5Y)21.56%
26-Week Price Return-62.45%
Quick Ratio (Annual)0.80x
13-Week Price Return92.40%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.35x
Enterprise Value$7.21M
Revenue / Share Growth (5Y)-27.89%
Asset Turnover (TTM)0.06x
Revenue / Employee (Annual)$27,700
Inventory Turnover (Annual)21.00x
Pretax Margin (Annual)-3959.41%
Cash / Share (Annual)$0.33
3-Month Return Std Dev194.50%
Gross Margin (5Y Avg)89.02%
Net Income / Employee (TTM)$-850,500
ROE (Last FY)-3992.26%
Net Interest Coverage (Annual)-107.00x
EPS Basic Excl Extra (Annual)$-1.58
Receivables Turnover (TTM)18.69x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.09
Receivables Turnover (Annual)3.53x
ROI (TTM)-423.84%
P/S Ratio (TTM)28.83x
Pretax Margin (5Y Avg)-23470.44%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$1.14
Price vs S&P 500 (52W)-101.61%
Year-to-Date Return-65.53%
5-Day Price Return-0.34%
EPS Normalized (Annual)$-1.58
ROA (5Y Avg)-162.94%
Net Profit Margin (Annual)-3959.41%
Month-to-Date Return-15.27%
Cash Flow / Share (TTM)$-3.99
EBITD / Share (Annual)$-1.72
Operating Margin (Annual)-4350.05%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-904.24%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.09
P/TBV (Quarterly)2.76x
P/B Ratio (Annual)29.23x
Inventory Turnover (TTM)31.00x
Pretax Margin (TTM)-3089.55%
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)84.14%
Beta0.66x
Revenue / Share (TTM)$0.02
ROE (TTM)-423.84%
52-Week Low$0.16
vGradeF
gGradeD
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.12est. -0.20
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Health Services(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BRTXBioRestorative Therapies, Inc. Common Stock (NV) | F | D | C | $0.41 |
| DVADaVita Inc. | C | C | B | $192.16 |
| FMSFresenius Medical Care AG | A | D | C | $22.03 |
| SHCSotera Health Company Common Stock | D | B | C | $15.62 |
| PGNYProgyny, Inc. Common Stock | C | B | B | $25.86 |
| AGLagilon health, inc. | B | C | A | $96.85 |
| MCTACharming Medical Limited Class A Ordinary Shares | F | F | A | $29.36 |
| VMDViemed Healthcare, Inc. Common Shares | C | C | B | $9.97 |
| QIPTQuipt Home Medical Corp. Ordinary Shares | B | B | B | $0.00 |
| PARKPark Dental Partners, Inc. Common Stock | B | C | C | $18.96 |
| OAKUOak Woods Acquisition Corporation Class A Ordinary Shares | — | F | B | $0.00 |
About
BioRestorative Therapies is a biotechnology company developing cell-based regenerative medicine therapies using adult stem cells. The company is advancing BRTX-100, an autologous mesenchymal stem cell therapy for disc and spine disorders, and a brown adipose-derived cell therapy program targeting obesity and metabolic diseases.